ResMed (RMD) Tops Q2 EPS by 22c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $253.06 +2.79%
EPS Growth %: +5.1%
Financial Fact:
Selling, general and administrative: 128.85M
Today's EPS Names:
ORPB, PBCO, SICP, More
EPS Growth %: +5.1%
Financial Fact:
Selling, general and administrative: 128.85M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q2 EPS of $1.00, $0.22 better than the analyst estimate of $0.78. Revenue for the quarter came in at $601 million versus the consensus estimate of $580.32 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- AppFolio (APPF) Tops Q3 EPS by 3c; Offers Outlook
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
Create E-mail Alert Related Categories
Corporate News, Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
